Trial · NCT06006117
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
NCT06006117, Phase 3, Recruiting, The Lymphoma Academic Research Organisation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma. Trials, record NCT06006117. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06006117
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
- NCT number
- NCT06006117
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 260 participants, estimated
- Lead sponsor
- The Lymphoma Academic Research Organisation
- Conditions
- Marginal Zone Lymphoma
- Interventions
- Mosunetuzumab (SC), Rituximab (R), Bendamustine, CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone), Lenalidomide
- First posted
- 2023-08-23
- Last updated
- 2026-06-15
Source ClinicalTrials.gov
Registered outcomes36
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) as determined by investigator | After 122 events = approximately 4.5 years and after 163 events = approximately 6.5 years (event = progression or death) | according to Lugano criteria 2014 |
| Secondary | Complete Response rate (CR) as determined by investigator (CR24) | 2 years | according to Lugano criteria 2014 |
| Secondary | Complete response rate (CR) by blinded central review (CR24) | 2 years | based on PET result according to Lugano Criteria 2014 |
| Secondary | Overall response rate (ORR) as determined by investigator | 6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine | according to Lugano Criteria 2014 |
| Secondary | Overall response rate (ORR) as determined by investigator | 12 months | according to Lugano Criteria 2014 |
| Secondary | Overall response rate (ORR) as determined by investigator | 24 months | according to Lugano Criteria 2014 |
| Secondary | Overall response rate (ORR) as determined by investigator | 36 months | according to Lugano Criteria 2014 |
| Secondary | Overall response rate (ORR) as determined by investigator | 48 months | according to Lugano Criteria 2014 |
| Secondary | Overall response rate (ORR) as determined by investigator | 60 months | according to Lugano Criteria 2014 |
| Secondary | Overall response rate (ORR) by blinded central review | 6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine | based on PET result according to Lugano Criteria 2014 |
1 to 10 of 36Source ClinicalTrials.gov
See all 36 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06006117
GET https://conductscience.org/api/trials/v1/NCT06006117/registered?page=2